Literature DB >> 26925202

Hepatitis C virus inhibitor synergism suggests multistep interactions between heat-shock protein 90 and hepatitis C virus replication.

Naoko Kubota1, Masataka Nomoto1, Gi-Wook Hwang1, Toshihiko Watanabe1, Michinori Kohara1, Takaji Wakita1, Akira Naganuma1, Shusuke Kuge1.   

Abstract

AIM: To address the effect of heat-shock protein 90 (HSP90) inhibitors on the release of the hepatitis C virus (HCV), a cell culture-derived HCV (JFH1/HCVcc) from Huh-7 cells was examined.
METHODS: We quantified both the intracellular and extracellular (culture medium) levels of the components (RNA and core) of JFH-1/HCVcc. The intracellular HCV RNA and core levels were determined after the JFH1/HCVcc-infected Huh-7 cells were treated with radicicol for 36 h. The extracellular HCV RNA and core protein levels were determined from the medium of the last 24 h of radicicol treatment. To determine the possible role of the HSP90 inhibitor in HCV release, we examined the effect of a combined application of low doses of the HSP90 inhibitor radicicol and the RNA replication inhibitors cyclosporin A (CsA) or interferon. Finally, we statistically examined the combined effect of radicicol and CsA using the combination index (CI) and graphical representation proposed by Chou and Talalay.
RESULTS: We found that the HSP90 inhibitors had greater inhibitory effects on the HCV RNA and core protein levels measured in the medium than inside the cells. This inhibitory effect was observed in the presence of a low level of a known RNA replication inhibitor (CsA or interferon-α). Treating the cells with a combination of radicicol and cyclosporin A for 24 h resulted in significant synergy (CI < 1) that affected the release of both the viral RNA and the core protein.
CONCLUSION: In addition to having an inhibitory effect on RNA replication, HSP90 inhibitors may interfere with an HCV replication step that occurs after the synthesis of viral RNA, such as assembly and release.

Entities:  

Keywords:  Cell culture-derived hepatitis C virus; Heat-shock protein 90 inhibitors; Hepatitis C virus; Hepatitis C virus RNA replication; Inhibition of hepatitis C virus release

Year:  2016        PMID: 26925202      PMCID: PMC4757651          DOI: 10.4254/wjh.v8.i5.282

Source DB:  PubMed          Journal:  World J Hepatol


  25 in total

Review 1.  Structure and functional relationships of Hsp90.

Authors:  Chrisostomos Prodromou; Laurence H Pearl
Journal:  Curr Cancer Drug Targets       Date:  2003-10       Impact factor: 3.428

2.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

Review 3.  Novel insights into hepatitis C virus replication and persistence.

Authors:  Ralf Bartenschlager; Michael Frese; Thomas Pietschmann
Journal:  Adv Virus Res       Date:  2004       Impact factor: 9.937

4.  A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems.

Authors:  T C Chou; P Talalay
Journal:  J Biol Chem       Date:  1977-09-25       Impact factor: 5.486

Review 5.  Epidemiology of hepatitis C virus infection.

Authors:  Miriam J Alter
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

6.  Heat-shock protein 90 is essential for stabilization of the hepatitis C virus nonstructural protein NS3.

Authors:  Saneyuki Ujino; Saori Yamaguchi; Kunitada Shimotohno; Hiroshi Takaku
Journal:  J Biol Chem       Date:  2009-01-16       Impact factor: 5.157

Review 7.  The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection.

Authors:  Ralf Bartenschlager; Volker Lohmann; Francois Penin
Journal:  Nat Rev Microbiol       Date:  2013-06-10       Impact factor: 60.633

8.  Cellular growth kinetics distinguish a cyclophilin inhibitor from an HSP90 inhibitor as a selective inhibitor of hepatitis C virus.

Authors:  Rudolf K F Beran; Ruchi Sharma; Amoreena C Corsa; Yang Tian; Justin Golde; Greta Lundgaard; William E Delaney; Weidong Zhong; Andrew E Greenstein
Journal:  PLoS One       Date:  2012-02-08       Impact factor: 3.240

9.  Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro.

Authors:  John M Robida; Heather B Nelson; Zhe Liu; Hengli Tang
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103

10.  Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations.

Authors:  Thomas Pietschmann; Margarita Zayas; Philip Meuleman; Gang Long; Nicole Appel; George Koutsoudakis; Stephanie Kallis; Geert Leroux-Roels; Volker Lohmann; Ralf Bartenschlager
Journal:  PLoS Pathog       Date:  2009-06-12       Impact factor: 6.823

View more
  1 in total

1.  A new advanced in silico drug discovery method for novel coronavirus (SARS-CoV-2) with tensor decomposition-based unsupervised feature extraction.

Authors:  Y-H Taguchi; Turki Turki
Journal:  PLoS One       Date:  2020-09-11       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.